A 65-year-old man with severe ARDS has been paralysed with cisatracurium for 48 hours. The ACURASYS and ROSE trials examined early NMB in ARDS. What was the key finding of the ROSE trial (2019)?ANMB significantly reduced mortalityBEarly continuous cisatracurium for 48 hours did NOT reduce mortality compared to a lighter sedation strategy (targeting RASS 0 to -1) without NMB in moderate-to-severe ARDS - suggesting that the benefit seen in ACURASYS may have been due to deep sedation in the control group rather than NMB itselfCNMB increased mortalityDNMB was only beneficial in mild ARDSEThe ROSE trial was stopped for benefitCheck my answer